In short
PF-07868489 is an investigational medication currently being studied for the treatment of Pulmonary Arterial Hypertension (PAH), a serious condition characterized by high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through the lungs, potentially damaging the right side of the heart. Clinical trials are underway to evaluate the safety, effectiveness, and long-term benefits of PF-07868489, which is administered as a subcutaneous injection. These studies include both initial trials with healthy participants and patients with PAH, as well as extension studies that allow continued treatment to assess long-term outcomes.
Key points
- PF-07868489 is an investigational medicine being studied for the treatment of Pulmonary Arterial Hypertension (PAH), a condition causing high blood pressure in lung arteries. The drug is administered as a subcutaneous injection every 4 weeks and is being evaluated in both initial clinical trials and long-term extension studies. Current trials include a Phase 1/2 study with healthy adults and PAH patients, as well as a Phase 2 open-label extension study allowing continued treatment for up to 111 weeks. Researchers are primarily measuring safety outcomes, changes in heart function markers (NT-proBNP), and how the drug behaves in the body. The ongoing studies will help determine if PF-07868489 is safe and effective as a potential treatment option for PAH patients.
At a glance
- Drug Name
- PF-07868489
- Condition Studied
- Pulmonary Arterial Hypertension (PAH)
- Administration Method
- Subcutaneous injection every 4 weeks
- Study Types
- Phase 1/2 trials with healthy participants and PAH patients; Phase 2 open-label extension study
- Study Designs
- Single ascending dose study (healthy adults); 24-week randomized, double-blind, placebo-controlled study (PAH patients); long-term open-label extension study
- Primary Outcome Measures
- Safety (adverse events, laboratory tests, vital signs, ECG parameters); Changes in NT-proBNP levels
- Secondary Outcome Measures
- Pharmacokinetics (how the drug moves through the body); Development of anti-drug antibodies
- Study Duration
- Initial studies: up to 24 weeks of treatment with follow-up to Day 253; Extension study: measurements up to week 111 (over 2 years)
What is PF-07868489?
PF-07868489 is an investigational medication being studied for the treatment of Pulmonary Arterial Hypertension (PAH). It is currently in clinical trials to evaluate its safety, effectiveness, and how it works in the body. The medication is not yet approved by regulatory agencies and is only available to patients participating in clinical studies. The drug is being developed as a potential new treatment option for people suffering from PAH, a serious condition affecting blood vessels in the lungs.
What is Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension is a condition characterized by high blood pressure in the arteries that carry blood from the heart to the lungs. This increased pressure makes it harder for the heart to pump blood through the lungs, potentially causing damage to the right side of the heart. PAH is a serious and progressive condition that can significantly impact a person's quality of life and survival.
The symptoms of PAH may include:
- Shortness of breath during routine activities
- Fatigue or weakness
- Chest pain or pressure
- Dizziness or fainting
- Swelling in the ankles, legs, or abdomen
How PF-07868489 is Administered
In clinical studies, PF-07868489 is administered through subcutaneous injections, which means the medication is injected just under the skin. Based on current research protocols, patients receive these injections:
- In long-term studies: Every 4 weeks
- In initial studies: As single doses for healthy volunteers (Part A) or as 6 regular injections over time for PAH patients (Part B)
The subcutaneous route of administration may offer convenience compared to some other PAH treatments that require continuous intravenous infusion or frequent oral dosing.
Clinical Studies of PF-07868489
PF-07868489 is being evaluated in multiple clinical trials to determine if it could be a safe and effective treatment for PAH. Current studies include:
Phase 1/2 Study: This study has two parts:
- Part A: Testing single ascending doses in healthy adult volunteers to assess safety, tolerability, and how the drug moves through the body (pharmacokinetics)
- Part B: A 24-week, randomized, double-blind, placebo-controlled study in adults with PAH to assess safety, how the drug works (pharmacodynamics), and initial signs of effectiveness
Phase 2 Open-Label Extension Study: This study allows patients who participated in earlier PF-07868489 studies to continue receiving the medication for a longer period (up to 111 weeks) to gather information about long-term safety and effectiveness.
In these studies, researchers carefully track how participants respond to the medication. Some participants receive PF-07868489, while others may receive a placebo (an injection with no active medication) for comparison, especially in the early phases of research.
Safety Monitoring
During the clinical trials, researchers closely monitor participants for any side effects or safety concerns. This monitoring includes:
- Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) - any unfavorable and unintended signs, symptoms, or diseases that occur during the study
- Laboratory tests to check blood counts, liver function, kidney function, and other body systems
- Vital sign measurements such as blood pressure, heart rate, and temperature
- Electrocardiogram (ECG) parameters to monitor heart function
- Anti-drug antibody (ADA) development - to see if the body develops an immune response to the medication
This comprehensive monitoring helps researchers understand the safety profile of PF-07868489 and identify any potential risks associated with its use.
Expected Benefits
While the full benefits of PF-07868489 are still being investigated, researchers are measuring several indicators that might show improvement in PAH, including:
- N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) levels: This is a blood marker that can indicate the amount of strain on the heart. Lower levels may suggest improvement in heart function.
- Other measurements of heart and lung function that may show improvement as treatment continues
If successful, PF-07868489 could potentially offer a new treatment option for people with PAH who may have limited alternatives or who don't respond well to existing treatments.
Ongoing Research
Research on PF-07868489 is ongoing, with studies designed to answer important questions about the medication:
- Pharmacokinetics: How the drug is absorbed, distributed, metabolized, and eliminated from the body
- Pharmacodynamics: How the drug affects the body and the underlying disease
- Long-term safety: Whether the drug remains safe when used over extended periods
- Efficacy: Whether the drug effectively improves symptoms and outcomes for people with PAH
The results of these studies will help determine whether PF-07868489 may eventually become an approved treatment option for PAH patients. Patients interested in learning more about this investigational treatment should speak with their healthcare providers about potential eligibility for clinical trials.